Evidence: well sourced. Imported from the supplied 65-Case Master Edition, dated September 19, 2026. Source links and classifications are retained as an attributed case account; import is not an independent source review.

Case at a glance

Case number
041
Date / range
2018–2019
Sector
Reproductive and heritable genetics
Genetic asset
Edited embryos and associated research/oversight records
Security principle
Heritable-Edit Governance Failure

Event summary

He Jiankui's embryo-editing experiment turned governance defects—questionable consent, forged or misleading oversight materials, premature clinical use, uncertain off-target effects, and heritable consequences—into permanent biological risk.

Source: pmc.ncbi.nlm.nih.gov — The He Jiankui CRISPR-Baby Experiment source 1.

Source: who.int — The He Jiankui CRISPR-Baby Experiment source 2.

The case in context

The embryo-editing experiment joined scientific uncertainty with failures of oversight and consent. A heritable intervention creates a different governance problem from a software change: its consequences cannot be handled through a routine rollback, and the people most directly affected could not authorize the decision.

The analysis should protect the children's privacy and avoid claiming that every long-term outcome is known. The case concerns a specific experiment and its governance, not a judgment that all gene editing is equivalent. Somatic treatment and heritable embryo editing require distinct descriptions of purpose, evidence, and affected parties.

Acquisition and processing

recruitment → embryo editing → inadequate/invalid oversight → implantation → live births → permanent and potentially heritable uncertainty

The sequence of events

  1. recruitment
  2. embryo editing
  3. inadequate/invalid oversight
  4. implantation
  5. live births
  6. permanent and potentially heritable uncertainty

What became inferable or exposed

Edited embryos and associated research/oversight records

He Jiankui's embryo-editing experiment turned governance defects—questionable consent, forged or misleading oversight materials, premature clinical use, uncertain off-target effects, and heritable consequences—into permanent biological risk.

Security dimensions

Confidentiality

The confidentiality question concerns edited embryos and associated research/oversight records. Exposure and further inference must be distinguished from the fact of collection or availability.

Integrity

The integrity question is whether the described material, permissions, processing, or interpretation can be relied upon. Heritable-Edit Governance Failure identifies the particular boundary examined here.

Availability

Access and continuity are assessed for the described event; potential effects are not presented as confirmed outages or losses.

Provenance

The relevant chain follows edited embryos and associated research/oversight records through the stages shown below. Missing public detail is not proof that internal records did not exist.

GeneticSecurity.org analysis

Genetic Exposure Radius

Not assessed

No single level is assigned where the supplied dossier gives a range, conditional outcome, or broad institutional consequence. The affected parties and proposed assessment are shown separately.

Confidence: not assigned. Classification: GeneticSecurity.org analysis.

Genetic Persistence Risk

Not assessed

Persistence depends on the specific biological material or information retained. A potential effect is not treated as an observed genomic disclosure.

Confidence: not assigned. Classification: GeneticSecurity.org analysis.

Genetic Provenance Integrity

Not assessed

A numeric provenance level is not inferred from the existence of a source or court record. It requires evidence of the relevant custody and processing controls.

Confidence: not assigned. Classification: GeneticSecurity.org analysis.

Proposed classification and its limits

Suggested GER: GER-1 initially, potentially generational. Suggested GPR: GPR-5. Suggested GPI: GPI-1/2 due to contested records and incomplete independent verification.

These are proposed classifications from the supplied case dossier. Conditional scores describe an assumed exposure; they are not evidence that it occurred. A single numeric value is left unassigned when the asset or outcome is not sufficiently bounded.

What this case does not prove

It does not prove all human gene editing is unethical or that every claimed outcome is known. Separate somatic therapy from heritable embryo editing.

Mitigations and lessons

  • Credible independent review
  • Trial registration
  • Validated preclinical evidence
  • Consent comprehension
  • Long-term welfare plans
  • Identity protection
  • Transparent assay provenance
  • Enforceable international norms

Primary sources

Secondary sources

No additional source listed. See the evidence notes for limitations.

Policy and standards

Genetic Security Policy and Standards

Review and correction history

Source edition: September 19, 2026. Imported case account; no substantive corrections recorded.

Correction policy and log

Cite this case

GS-CASE-041. The CRISPR Babies: A Heritable Change Without a Trustworthy Control Plane. GeneticSecurity.org. https://geneticsecurity.org/cases/041-he-jiankui-crispr-babies-governance/